journal article·2025-09-23

Self-Assembled Nanoparticle Vaccines Elicit Robust Protective Immune Responses against Type O Foot-and-Mouth Disease Virus Infection

Nan Cao, Yamei Li, Qiongqiong Zhao, Manman Yao, Xujiao Ren, Linxing Tian, Zihui Hu, Feifei Diao, Hehai Li, Zengjun Lu, Guibo Rao, Huawei Zhang, Kun Li, Sheng Cao, Xiangmin Li, Ping Qian

ACS Nano· Volume 19· Issue 37
Publisher page

Abstract

Foot-and-mouth disease virus (FMDV), a critical pathogen in the global livestock industry, has long been a focal point of international disease control strategies. This study developed a nanoparticle-based FMDV vaccine platform. We fused the FMDV immunodominant epitope (VP1-G-H-loop) and T-cell epitope (T 3D ) with the nanoparticle scaffold lumazine synthase (LS), efficiently producing the T 3D -LS-LOOP nanoparticle vaccine using the prokaryotic expression system Escherichia coli (BL21). Mouse experiments showed that the T 3D -LS-LOOP nanoparticle vaccine induced a more robust immune response than the LS-LOOP nanoparticle vaccine. To evaluate the role of different scaffolds in FMDV antigen presentation, we substituted the LS scaffold with Ferritin (Ft) and β- annulus peptide (β) nanoparticles, generating T 3D -β-LOOP and T 3D -Ft-LOOP nanoparticle proteins. The results demonstrated that the LS scaffold-mediated T 3D -LS-LOOP nanoparticle vaccine induced the highest neutralizing antibody (NAb) titers (1:2 8.5 ) and an effective T-cell immune response, providing 100% protection in mice, outperforming T 3D -Ft-LOOP (66.7%) and T 3D -β-LOOP (83.3%) nanoparticle vaccines. Encouragingly, the T 3D -LS-LOOP nanoparticle vaccine also induced high NAb titers against different lineages (Mya98/Cathay/PanAsia) of type O FMDV and a strong Th2-biased cellular immune response in swine, with no adverse reactions observed postvaccination, achieving complete protection against a type O FMDV challenge in swine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Animal Disease Management and Epidemiology · Viral Infections and Immunology Research · Vector-Borne Animal Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory

Huazhong Agricultural University

College of Veterinary Medicine

Key Laboratory of Preventive Veterinary Medicine in Hubei Province

The Cooperative Innovation Center for Sustainable Pig Production

State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute

Chinese Academy of Agricultural Sciences

Shanghai Shen Lian Biomedical Corporation

State Key Laboratory of Virology and Biosafety

Wuhan Institute of Virology, Chinese Academy of Sciences

Wuhan Keqian Biological Co, Ltd.

Hubei Jiangxia Laboratory

Funding

Huazhong Agricultural University · National Key Research and Development Program of China · National Natural Science Foundation of China

References (73)

Show source-provided references
1. 10.1111/j.1865-1682.2011.01204.x10.1111/j.1865-1682.2011.01204.x ↗
2. Zientara S. · La Revue du praticien · 2021 · 71 · 102
3. 10.1016/S0168-1702(02)00261-710.1016/S0168-1702(02)00261-7 ↗
4. 10.1186/1297-9716-44-11610.1186/1297-9716-44-116 ↗
5. 10.1128/CMR.17.2.465-493.200410.1128/CMR.17.2.465-493.2004 ↗
6. 10.1007/3-540-27109-0_310.1007/3-540-27109-0_3 ↗
7. 10.1128/JVI.79.10.6487-6504.200510.1128/JVI.79.10.6487-6504.2005 ↗
8. 10.3390/v1304057210.3390/v13040572 ↗
9. 10.1016/j.ijbiomac.2023.12883710.1016/j.ijbiomac.2023.128837 ↗
10. 10.1128/JVI.74.1.272-280.200010.1128/JVI.74.1.272-280.2000 ↗
11. 10.1051/vetres:200110610.1051/vetres:2001106 ↗
12. 10.1016/j.vaccine.2019.05.01910.1016/j.vaccine.2019.05.019 ↗
13. 10.3390/vaccines703009010.3390/vaccines7030090 ↗
14. 10.3389/fimmu.2020.62153710.3389/fimmu.2020.621537 ↗
15. 10.1186/1743-422X-9-6610.1186/1743-422X-9-66 ↗
16. 10.1586/14760584.2016.114004210.1586/14760584.2016.1140042 ↗
17. 10.1016/j.vetmic.2016.12.01810.1016/j.vetmic.2016.12.018 ↗
18. 10.1016/j.addr.2005.11.00310.1016/j.addr.2005.11.003 ↗
19. 10.3390/vaccines1011181710.3390/vaccines10111817 ↗
20. 10.1080/07388551.2018.155461910.1080/07388551.2018.1554619 ↗
21. 10.1007/s00705-019-04216-x10.1007/s00705-019-04216-x ↗
22. 10.1186/s13567-025-01485-010.1186/s13567-025-01485-0 ↗
23. 10.1099/0022-1317-82-7-171310.1099/0022-1317-82-7-1713 ↗
24. 10.1016/j.virusres.2011.02.00310.1016/j.virusres.2011.02.003 ↗
25. 10.1080/21645515.2017.133023610.1080/21645515.2017.1330236 ↗
26. 10.1016/j.vetimm.2007.06.02910.1016/j.vetimm.2007.06.029 ↗
27. 10.1006/viro.1999.971710.1006/viro.1999.9717 ↗
28. 10.1016/j.jviromet.2006.05.01910.1016/j.jviromet.2006.05.019 ↗
29. 10.1080/14760584.2020.179109010.1080/14760584.2020.1791090 ↗
30. 10.1155/2019/830364810.1155/2019/8303648 ↗
31. 10.1186/s12896-016-0285-610.1186/s12896-016-0285-6 ↗
32. 10.3389/fonc.2018.0040410.3389/fonc.2018.00404 ↗
33. 10.3390/vaccines1011192010.3390/vaccines10111920 ↗
34. 10.1074/jbc.C117.79031110.1074/jbc.C117.790311 ↗
35. 10.1016/S0022-2836(02)00116-X10.1016/S0022-2836(02)00116-X ↗
36. 10.1006/jmbi.2000.374210.1006/jmbi.2000.3742 ↗
37. 10.1021/bi047848a10.1021/bi047848a ↗
38. 10.1074/jbc.M70172420010.1074/jbc.M701724200 ↗
39. 10.1074/jbc.M31203520010.1074/jbc.M312035200 ↗
40. 10.1104/pp.90.2.58610.1104/pp.90.2.586 ↗
41. 10.1016/j.nano.2013.11.00310.1016/j.nano.2013.11.003 ↗
42. 10.1016/j.vaccine.2020.06.06310.1016/j.vaccine.2020.06.063 ↗
43. 10.1002/anie.20100460610.1002/anie.201004606 ↗
44. 10.47665/tb.38.1.02710.47665/tb.38.1.027 ↗
45. 10.4236/jbm.2013.1300510.4236/jbm.2013.13005 ↗
46. 10.3389/fvets.2020.0049810.3389/fvets.2020.00498 ↗
47. 10.1016/j.vaccine.2016.06.00810.1016/j.vaccine.2016.06.008 ↗
48. 10.1016/j.vetmic.2024.11019810.1016/j.vetmic.2024.110198 ↗
49. 10.3390/v1408181010.3390/v14081810 ↗
50. 10.7717/peerj.482310.7717/peerj.4823 ↗
51. 10.1038/298030a010.1038/298030a0 ↗
52. 10.1002/btpr.46310.1002/btpr.463 ↗
53. 10.1128/AEM.00743-0810.1128/AEM.00743-08 ↗
54. 10.1021/nl504798g10.1021/nl504798g ↗
55. 10.7150/ntno.1979610.7150/ntno.19796 ↗
56. 10.1016/j.ijpharm.2005.03.03510.1016/j.ijpharm.2005.03.035 ↗
57. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
58. 10.1021/acsnano.6b0734310.1021/acsnano.6b07343 ↗
59. 10.1038/nri286810.1038/nri2868 ↗
60. 10.3390/vaccines1209107110.3390/vaccines12091071 ↗
61. 10.1016/j.vetmic.2023.10979910.1016/j.vetmic.2023.109799 ↗
62. 10.1039/C9NR05549E10.1039/C9NR05549E ↗
63. 10.1016/j.vetmic.2015.12.00410.1016/j.vetmic.2015.12.004 ↗
64. 10.1016/j.vaccine.2018.10.03010.1016/j.vaccine.2018.10.030 ↗
65. 10.1016/j.vaccine.2022.09.05810.1016/j.vaccine.2022.09.058 ↗
66. 10.1038/ncomms1466310.1038/ncomms14663 ↗
67. 10.1016/j.immuni.2020.11.01510.1016/j.immuni.2020.11.015 ↗
68. 10.1038/s41586-021-03819-210.1038/s41586-021-03819-2 ↗
69. 10.1038/nmeth.416910.1038/nmeth.4169 ↗
70. 10.1002/pro.323510.1002/pro.3235 ↗
71. 10.3390/vaccines1004063110.3390/vaccines10040631 ↗
72. 10.3389/fmicb.2022.80560610.3389/fmicb.2022.805606 ↗
73. 10.3390/v1204036910.3390/v12040369 ↗